

Special Issue

Advances in HSV

Message from the Guest Editors

Herpes Simplex virus (HSV1 and HSV2) infections are quite common in humans. According to the WHO, approximately 3.8 billion people worldwide under the age of 50 are infected with HSV-1, while an estimated 520 million people worldwide aged 15–49 have contracted HSV-2. HSV is a neurovirulent virus. After infection, HSV is transported through axons to the neuronal soma in the sensory ganglia, where they can establish lifelong latency. The virus can become reactivated and travel via anterograde axonal transport to peripheral sites, where it can cause development of painful lesions. HSV-1 is known to cause oral lesions, whereas HSV-2 generally spreads via sexual contact and causes genital herpes. In addition to oral infection, HSV-1 can cause ocular herpes, also known as herpes simplex keratitis (HSK), a condition that is quite prevalent worldwide. HSK, a type of herpes simplex keratitis, is a major cause of vision loss due to eye infections. Both viruses can also cause neurological complications, with HSV-2 being the primary cause of neonatal herpes encephalitis. Our aim in launching this Special Issue, “Advances in HSV”, is to publish review and research articles on HSV infections

Guest Editors

Prof. Dr. Susmit Suvas

School of Medicine, Wayne State University, Detroit, MI, USA

Prof. Dr. James Chodosh

Department of Ophthalmology & Visual Sciences, The University of New Mexico, Albuquerque, NM, USA

Deadline for manuscript submissions

closed (31 March 2026)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/246527

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).